These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 15134278)

  • 1. Serotonin receptor ligands and the treatment of obesity.
    Vickers SP; Dourish CT
    Curr Opin Investig Drugs; 2004 Apr; 5(4):377-88. PubMed ID: 15134278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders.
    Heal DJ; Smith SL; Fisas A; Codony X; Buschmann H
    Pharmacol Ther; 2008 Feb; 117(2):207-31. PubMed ID: 18068807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis.
    de Boer SF; Koolhaas JM
    Eur J Pharmacol; 2005 Dec; 526(1-3):125-39. PubMed ID: 16310183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin conflict in sleep-feeding.
    Nonogaki K
    Vitam Horm; 2012; 89():223-39. PubMed ID: 22640616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting 5-HT receptors for the treatment of obesity.
    Sargent BJ; Henderson AJ
    Curr Opin Pharmacol; 2011 Feb; 11(1):52-8. PubMed ID: 21330209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets.
    Terry AV; Buccafusco JJ; Wilson C
    Behav Brain Res; 2008 Dec; 195(1):30-8. PubMed ID: 18241938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing the effects of 5-HT(2C) receptor ligands on motor activity and feeding behaviour in 5-HT(2C) receptor knockout mice.
    Fletcher PJ; Tampakeras M; Sinyard J; Slassi A; Isaac M; Higgins GA
    Neuropharmacology; 2009 Sep; 57(3):259-67. PubMed ID: 19501602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphoinositide system-linked serotonin receptor subtypes and their pharmacological properties and clinical correlates.
    Pandey SC; Davis JM; Pandey GN
    J Psychiatry Neurosci; 1995 May; 20(3):215-25. PubMed ID: 7786883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the neuroendocrine role of serotonin.
    Jørgensen HS
    Dan Med Bull; 2007 Nov; 54(4):266-88. PubMed ID: 18208678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Implication of serotonin in the control of vigilance states as revealed by knockout-mouse studies].
    Adrien J
    J Soc Biol; 2004; 198(1):30-6. PubMed ID: 15146953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective serotonin receptor stimulation of the medial nucleus accumbens causes differential effects on food intake and locomotion.
    Pratt WE; Blackstone K; Connolly ME; Skelly MJ
    Behav Neurosci; 2009 Oct; 123(5):1046-57. PubMed ID: 19824770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of ingestive behaviour.
    Samanin R; Garattini S
    Therapie; 1996; 51(2):107-15. PubMed ID: 8763044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-HT(4) receptors: history, molecular pharmacology and brain functions.
    Bockaert J; Claeysen S; Compan V; Dumuis A
    Neuropharmacology; 2008 Nov; 55(6):922-31. PubMed ID: 18603269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7).
    Glennon RA
    J Med Chem; 2003 Jul; 46(14):2795-812. PubMed ID: 12825922
    [No Abstract]   [Full Text] [Related]  

  • 15. Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.
    Smith BM; Smith JM; Tsai JH; Schultz JA; Gilson CA; Estrada SA; Chen RR; Park DM; Prieto EB; Gallardo CS; Sengupta D; Thomsen WJ; Saldana HR; Whelan KT; Menzaghi F; Webb RR; Beeley NR
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1467-70. PubMed ID: 15713408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor.
    Parker MA; Marona-Lewicka D; Lucaites VL; Nelson DL; Nichols DE
    J Med Chem; 1998 Dec; 41(26):5148-9. PubMed ID: 9857084
    [No Abstract]   [Full Text] [Related]  

  • 17. Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents.
    Holenz J; Pauwels PJ; Díaz JL; Mercè R; Codony X; Buschmann H
    Drug Discov Today; 2006 Apr; 11(7-8):283-99. PubMed ID: 16580970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple serotonin receptors: opportunities for new treatments for obesity?
    Dourish CT
    Obes Res; 1995 Nov; 3 Suppl 4():449S-462S. PubMed ID: 8697043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational approaches to the design of novel 5-HT6 R ligands.
    Ivanenkov YA; Majouga AG; Veselov MS; Chufarova NV; Baranovsky SS; Filkov GI
    Rev Neurosci; 2014; 25(3):451-67. PubMed ID: 24867282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-HT receptors: implications for the neuropharmacology of alcohol and alcoholism.
    Overstreet DH; Rezvani AH; Pucilowski O; Janowsky DS
    Alcohol Alcohol Suppl; 1994; 2():205-10. PubMed ID: 8974337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.